Organization
CIBERONC
12 abstracts
Abstract
First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).Org: Sackler School of Medicine, Hospital Universitario Fundación Jiménez Díaz, McGill University and MUHC, Sungkyunkwan University School of Medicine, Hospital Germans Trias i Pujol,
Abstract
TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).Org: National Cancer Center Hospital East, Kashiwa, Japan, National Cheng Kung University, Daiichi Sankyo Inc., Taichung Veterans General Hospital, Mayo Clinic,
Abstract
Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.Org: GEICO, Arcagy-Gineco, NSGO-CTU, SAKK, BGOG,
Abstract
Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1.Org: Clínica Universidad de Navarra and CIBEREHD, CIMA, CIBERONC, IDISNA, Myeloma Center,
Abstract
Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.Org: Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital Universitario Son Espases, Hospital Arnau de Vilanova; GEICAM Spanish Breast Cancer Group,
Abstract
The CIRCULATE Spain study: Circulating tumor DNA based decision for adjuvant treatment in localized colon cancer.Org: INCLIVA Biomedical Research Institute, University of Valencia, Instituto Carlos III, CIBERONC, Biostatistics Unit,
Abstract
Development of CT-based radiomic model to predict 5-year progression-free survival (PFS) in locally advanced head and neck squamous cell carcinoma (LAHNSCC) treated with definitive chemoradiation.Org: INCLIVA Biomedical Research Institute, QUIBIM SL, Quibim S.L., Instituto Carlos III, CIBERONC,
Abstract
EXCALIBER-RRMM: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).Org: Winship Cancer Center of Emory University, St. Vincent’s Hospital, University of Melbourne, National and Kapodistrian University of Athens, Clínica Universidad de Navarra and CIBEREHD,
Abstract
Spatially resolved multi-region transcriptomic subtyping and assessment of gene expression profiles associated with long-term benefit from chemo-immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).Org: Hospital Universitario 12 de Octubre, Hospital Teresa Herrera-Materno Infantil, Complejo Hospitalario Universitario A Coruna, Hospital Universitario Regional Málaga, Fundacion Jimenez Diaz University Hospital,
Abstract
Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: Results from the observational study GEM1801.Org: Hospital Universitario San Pedro de Alcántara, Unidad Intercentros de Oncología, Hospitales Universitarios Regional y Virgen de la Victoria (HURyVV), Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Hospital Universitari Vall d’Hebron y Vall Hebrón Institute of Oncology (VHIO),
Abstract
Obesity and toxic habits as avoidable determinants of chronic peripheral neuropathy induced by chemotherapy (NPCIQ): NeuroPredict project.Org: Reina Sofía University Hospital, Hospital Universitario Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)–H. Universitario Reina Sofía, Universidad de Córdoba, GEICAM Spanish Breast Cancer Group, Barcelona, Spain, CIBERONC,
Abstract
Analysis of the applicability of the mHealth ALIBIRD platform and its impact on the follow-up of patients with lung cancer.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Infanta Sofía University Hospital, Telemedicine and Bioengineering Biomedical Engineering and Telemedicine Centre, Center for Biomedical Technology, Universidad Politécnica de Madrid,